Marc Raynaud’s research focused on ‘𝘋𝘺𝘯𝘢𝘮𝘪𝘤 𝘱𝘳𝘦𝘥𝘪𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘬𝘪𝘥𝘯𝘦𝘺-𝘨𝘳𝘢𝘧𝘵 𝘴𝘶𝘳𝘷𝘪𝘷𝘢𝘭 𝘸𝘪𝘵𝘩 𝘢𝘳𝘵𝘪𝘧𝘪𝘤𝘪𝘢𝘭 𝘪𝘯𝘵𝘦𝘭𝘭𝘪𝘨𝘦𝘯𝘤𝘦: 𝘈𝘯 𝘪𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘴𝘵𝘶𝘥𝘺 𝘰𝘧 𝘥𝘦𝘦𝘱 𝘤𝘰𝘩𝘰𝘳𝘵𝘴 𝘰𝘧 𝘬𝘪𝘥𝘯𝘦𝘺 𝘳𝘦𝘤𝘪𝘱𝘪𝘦𝘯𝘵𝘴’, whilst Nicola de Stefano presented the study: ‘𝘌𝘹𝘵𝘳𝘢𝘤𝘦𝘭𝘭𝘶𝘭𝘢𝘳 𝘷𝘦𝘴𝘪𝘤𝘭𝘦𝘴 𝘧𝘳𝘰𝘮 𝘩𝘶𝘮𝘢𝘯 𝘭𝘪𝘷𝘦𝘳 𝘴𝘵𝘦𝘮 𝘤𝘦𝘭𝘭𝘴 𝘳𝘦𝘥𝘶𝘤𝘦 𝘪𝘯𝘫𝘶𝘳𝘺 𝘪𝘯 𝘢 𝘮𝘰𝘥𝘦𝘭 𝘰𝘧 𝘯𝘰𝘳𝘮𝘰𝘵𝘩𝘦𝘳𝘮𝘪𝘤 𝘱𝘦𝘳𝘧𝘶𝘴𝘪𝘰𝘯 𝘰𝘧 𝘳𝘢𝘵 𝘪𝘴𝘤𝘩𝘦𝘮𝘪𝘤 𝘭𝘪𝘷𝘦𝘳’.
Identification and characterization of trajectories of cardiac allograft vasculopathy after heart transplantation
One of the most common reasons for long-term graft failure and patient death is an accelerated form of coronary artery disease called cardiac allograft vasculopathy. It is a frequent complication that affects up to half of patients within 10 years following heart transplantation. Yet, until now, little has been known about the different evolutive profiles of cardiac allograft vasculopathy and their risk factors.
Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study
The members of the Paris Transplant Group are present at the SFT congress which will take place from December 3, 2019 in Bordeaux, France.
The team of the Paris Transplant Group has been awarded at the ESOT 2019 congress in Copenhagen for its many contribution in the field of transplantation.
The Prize is given to a single Institution having submitted at least 5 abstracts for the event and granted with the best score. The Paris Transplant Group is very pleased to won this European award twice in a row.
Check out the contribution submitted by the Group on the ESOT website: esotcongress.org.
Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance
Using a new approach based on validated analytical methods and computer simulations, this work revealed that French transplant centres are much more likely to transplant kidneys from older donors than their American counterparts, and that this effectively increases the number of patients transplanted.
Paris Transplant Group
Our global aim is to accelerate the translation of immunological and gene expression discoveries into the clinical field by filling the gap between basic science and applied biomedical researches.